These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33335561)

  • 21. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
    Goodarzi R; Sabzian K; Shishehbor F; Mansoori A
    Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Stachowska E; Portincasa P; Jamioł-Milc D; Maciejewska-Markiewicz D; Skonieczna-Żydecka K
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33187278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis.
    Theodoridis X; Kalopitas G; Vadarlis A; Bakaloudi DR; Gkiourtzis Ν; Dionysopoulos G; Karanika E; Tsekitsidi E; Chourdakis M
    Pharmacol Ther; 2022 Dec; 240():108294. PubMed ID: 36183848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
    Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.
    Houttu V; Bouts J; Vali Y; Daams J; Grefhorst A; Nieuwdorp M; Holleboom AG
    Front Endocrinol (Lausanne); 2022; 13():1032164. PubMed ID: 36407307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
    Lavine JE; Schwimmer JB; Van Natta ML; Molleston JP; Murray KF; Rosenthal P; Abrams SH; Scheimann AO; Sanyal AJ; Chalasani N; Tonascia J; Ünalp A; Clark JM; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
    JAMA; 2011 Apr; 305(16):1659-68. PubMed ID: 21521847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Vitamin E on Clinical Outcomes in Patients With Non-alcoholic Fatty Liver Disease: A Meta-Analysis.
    Karedath J; Javed H; Ahsan Talpur F; Lal B; Kumari A; Kivan H; Anirudh Chunchu V; Hirani S
    Cureus; 2022 Dec; 14(12):e32764. PubMed ID: 36686141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis.
    Lin M; Zeng H; Deng G; Lei J; Li J
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101530. PubMed ID: 33272889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effectiveness of eHealth Interventions on Lifestyle Modification in Patients With Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-analysis.
    Kwon OY; Choi JY; Jang Y
    J Med Internet Res; 2023 Jan; 25():e37487. PubMed ID: 36689264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis.
    Amini-Salehi E; Hassanipour S; Keivanlou MH; Shahdkar M; Orang Goorabzarmakhi M; Vakilpour A; Joukar F; Hashemi M; Sattari N; Javid M; Mansour-Ghanaei F
    Nutr Rev; 2024 May; 82(6):815-830. PubMed ID: 37550264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on the correlation between type 2 diabetes mellitus combined with non-alcoholic steatohepatitis and aerobic exercise performance].
    Zhang J; Li L; Yu HY; Li Y; Wang FM; Di FS
    Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1068-1074. PubMed ID: 38016772
    [No Abstract]   [Full Text] [Related]  

  • 36. The Effects of Combined Vitamin E and C for Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Poonyam P; Kritsanaviparkporn C; Chommaitree P; Soodcharoen A
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2891-2899. PubMed ID: 36172650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
    Komolafe O; Buzzetti E; Linden A; Best LM; Madden AM; Roberts D; Chase TJ; Fritche D; Freeman SC; Cooper NJ; Sutton AJ; Milne EJ; Wright K; Pavlov CS; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013157. PubMed ID: 34280304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Guo XF; Wang C; Yang T; Li S; Li KL; Li D
    Food Funct; 2020 Sep; 11(9):7389-7399. PubMed ID: 32966467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.